TIS 0.00% 0.0¢ tissue therapies limited

the report is out, page-21

  1. 370 Posts.
    From the AGM presentation in November they look like they will not selling 'version 1'. It costs too much produce. Hence version 2 and revenue second half 2011 after Q4 2010 trials end and approvals H1 of 2011.

    Try reading the AGM presentation, it's all in there.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.